Fully Human Antibodies, Acceleration of Discovery & Development
Mission
Individual Project Design, Fee for Service or Milestone-based
Contract Research, R&D Services
Partnered R&D, Collaborations, Licensing
Pipeline & Partnering
Follow a manual added link
Breaking News
Ymmunobio signs collaboration agreement with YUMAB
Swiss biotech company Ymmunobio AG will optimize its cancer-directed antibody development programme using YUMABs antibody discovery platform .
Bridging the gap from target to lead
The success of next generation antibody drug development relies on comprehensive discovery technologies and strategies.
YUMAB bridges the gap between research innovation and novel therapies. Our advanced discovery platform provides access to challenging targets, enables new formats, and accelerates the development of human antibodies at a high success rate.
From target discovery to fully characterized lead – our experienced team leads biotech and pharma teams worldwide through the development process as your trusted, de-risking partner.
and watch our coporate image video:
News & Events
BIOCOPY AND YUMAB ANNOUNCE PARTNERSHIP
September 2023
Emmedingen/Braunschweig – BioCopy and YUMAB announce a partnership to fight cancer by accelerating the develoment of highly specific antibodies against pHLA targets.
CRO / R&D Services
YUMAB offers contract research, technologies and R&D services for the discovery and development of fully human, therapeutic antibodies.
YUMAB® Platform, Partnering
YUMAB also provides partnering and collaboration strategies to provide access to our technologies and expertise for academic spin-offs and start-up companies without the burden of technology access fees.
Contact
SEND US AN E-MAIL
YUMAB GMBH
Phone: (+49) 531-481170-0
Email: info@yumab.com
YUMAB Inc.
1100 South Tower
225 Peachtree Street NE
Atlanta, GA 30303 – USA
Phone: (+49) 531 481170-0
Email: info@yumab.com
YUMAB GmbH
Science Campus Braunschweig-Süd
Inhoffenstr. 7
38124 Braunschweig – Germany
Phone: +49 531 481170-0
Fax: +49-531 481170-17
